US63909J1088 - Common Stock
NAUTILUS BIOTECHNOLOGY INC
NASDAQ:NAUT (4/25/2024, 3:52:24 PM)
After market: 2.31 -0.05 (-2.12%)2.36
-0.04 (-1.67%)
Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. Its Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
NAUTILUS BIOTECHNOLOGY INC
2701 Eastlake Ave East
Seattle WASHINGTON
P: 12063332001
CEO: Adam Stone
Employees: 160
Website: https://www.nautilus.bio/
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein...
Nautilus Biotechnology files prospectus for $300M mixed securities shelf.
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome...
Here you can normally see the latest stock twits on NAUT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: